Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2407
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study ; volume:8 ; number:1 ; day:13 ; month:8 ; year:2008 ; pages:1-10 ; date:12.2008
BMC cancer ; 8, Heft 1 (13.8.2008), 1-10, 12.2008

Creator
Razis, Evangelia
Contributor
Briasoulis, Evangelos
Brettu, Elenē
Skarlos, Dimosthenis V.
Papamichael, Dimitrios
Kostopoulos, Ioannis
Samantas, Epaminontas
Xanthakis, Ioannis
Bobos, Mattheos
Galanidi, Eleni
Bai, Maria
Gikonti, Ioanna
Koukouma, Alona
Kafiri, Georgia
Papakostas, Pavlos
Kalogeras, Konstantine T.
Kosmidis, Paris
Fountzilas, George
SpringerLink (Online service)

DOI
10.1186/1471-2407-8-234
URN
urn:nbn:de:1111-2016030346142
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:31 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Razis, Evangelia
  • Briasoulis, Evangelos
  • Brettu, Elenē
  • Skarlos, Dimosthenis V.
  • Papamichael, Dimitrios
  • Kostopoulos, Ioannis
  • Samantas, Epaminontas
  • Xanthakis, Ioannis
  • Bobos, Mattheos
  • Galanidi, Eleni
  • Bai, Maria
  • Gikonti, Ioanna
  • Koukouma, Alona
  • Kafiri, Georgia
  • Papakostas, Pavlos
  • Kalogeras, Konstantine T.
  • Kosmidis, Paris
  • Fountzilas, George
  • SpringerLink (Online service)

Other Objects (12)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan

Right- and left-sided colorectal cancers respond differently to cetuximab

Right- and left-sided colorectal cancers respond differently to cetuximab

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer

Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer

Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer

Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer

Can we accurately report PTEN status in advanced colorectal cancer?

Can we accurately report PTEN status in advanced colorectal cancer?

Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts

Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer

Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer

Related objects